Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Small-Cap · Gmo

GMO U.S. Small Cap Value Fund (GCAVX)

Ticker GCAVX · Since 2019-07-02 · · Holdings as of May 31, 2026

Expense ratio
0.5%$50/yr per $10k
5-yr return
+12.9%annualized
1-yr return
+15.3%as of Dec 2025
Net assets
$45.3Mall share classes
Holdings
243

Bottom line

Is GCAVX a good fund? The bottom line

GCAVX is an actively managed small-cap mutual fund from Gmo.

It charges 0.5% — about $50 a year on every $10,000 invested, cheaper than 89% of small-cap funds we track.

It returned +15.3% over one year, +12.9% a year over five years (as of Dec 31, 2025, per its prospectus).

With $45.3 million in net assets and 243 holdings, its largest position is BorgWarner Inc (2.4%) and the top 10 make up 18.9% of the portfolio.

What stands out

  • Low cost: cheaper than 89% of small-cap peers
  • 5-year return beat 97% of category peers
  • Broadly diversified (243 holdings)

What to watch

  • Small fund ($45.3 million) — small funds are likelier to close

Updated Nov 19, 2026

What GCAVX invests in

Total return.

"GMO seeks to achieve the Funds investment objective by investing the Funds assets primarily in equities of U.S. small-cap companies. GMO selects the securities the Fund buys and sells based on its evaluation of companies published financial information, securities prices, equity and other markets, the overall global economy, and governmental policies. In selecting securities for the Fund, GMO uses a combination of proprietary quantitative investment methods to identify U.S. equities GMO believes have positive return potential relative to other U.S. equities. Some of these methods evaluate individual companies or groups of companies based on the ratio of their security price to historical financial information and forecasted financial information, such as return on invested capital, profitability, cash flow and earnings, and a comparison of these ratios to current and historical…

From the fund's prospectus (filed Oct 20, 2026).

GCAVX performance

Fund calendar-year total returns, 2020–2025 2020: +2.4%; 2021: +35.7%; 2022: −14.0%; 2023: +22.7%; 2024: +11.2%; 2025: +15.3% +2.4% 2020 +35.7% 2021 −14.0% 2022 +22.7% 2023 +11.2% 2024 +15.3% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
GCAVX+15.3%+12.9%—
Small-Cap median+7.6%+7.0%+9.2%

Source: Fund prospectus, as of Dec 31, 2025

Full GCAVX performance history →

What GCAVX costs

On a $10,000 investment, GCAVX's 0.5% expense ratio costs about $50 a year. The prospectus estimates $841 in total costs over 10 years (assuming 5% annual returns). The median small-cap fund charges 0.99%.

See the full GCAVX fee table →

GCAVX top 10 holdings

#Holding% of fund
1BorgWarner Inc2.44%
2Axcelis Technologies Inc2.27%
3Skyworks Solutions Inc1.91%
4ArcBest Corp1.89%
5Enova International Inc1.85%
6Cirrus Logic Inc1.84%
7Lear Corp1.72%
8Lincoln National Corp1.68%
9Jackson Financial Inc1.68%
10Macy's Inc1.64%

Source: SEC Form N-PORT, period ended May 31, 2026

The top 10 make up 18.9% of the fund. See all top 25 holdings and asset mix →

Alternatives to GCAVX

More funds like GCAVX →

GCAVX FAQ

What is the expense ratio of GCAVX?
GCAVX's expense ratio is 0.5%, which works out to about $50 a year for every $10,000 invested. The prospectus estimates total costs of $841 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is GCAVX a good investment?
It depends on your goals, but the data points to: low cost: cheaper than 89% of small-cap peers; 5-year return beat 97% of category peers; broadly diversified (243 holdings); small fund ($45.3 million) — small funds are likelier to close. This is general information, not personalized advice.
What does GCAVX hold?
GCAVX's largest holdings are BorgWarner Inc (2.4%), Axcelis Technologies Inc (2.3%), Skyworks Solutions Inc (1.9%), ArcBest Corp (1.9%), Enova International Inc (1.9%). It holds 243 positions in total as of May 31, 2026 (SEC Form N-PORT).
What is GCAVX's 5-year return?
GCAVX returned +12.9% a year over the five years ending Dec 31, 2025. Past performance does not guarantee future results.
Who manages GCAVX?
GCAVX is offered by Gmo through Gmo Trust.